Keywords: Pfizer, Protalix, M&A, Novo Nordisk, Filling plant, Hemispherx, Ampligen, USA, FDA, Idenix, Hepatitis C
New briefs on Pfizer interest in Protalix; Novo Nordisk warning letter; Hemispherx' Ampligen; and Idenix' hep C program
Article | 06 February 2013
Israeli drug developer Protalix BioTherapeutics (NYSE-AMEX: OLX) saw its shares surge 14.2% yesterday following an Israeli press report that US drugs ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Is failure to adopt business process management putting the pharma industry at risk?
- Sanofi and Regeneron's dupilumab shows 87% reduction in risk of asthma exacerbations
- Pfizer to split-off remaining 80% interest in Zoetis
